In one paragraphArticle in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Bruna PanizzuttiSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0002-8825-734X Chiara Cristina BortolasciSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
Megan EllisSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0001-9790-5735 Briana SpoldingSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0001-7453-4580 Courtney SwintonSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
Trang T T TruongSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0001-9301-5911 Cassie FieldSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0009-0000-7845-7818 Zoe Shih-Jung LiuSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0002-0269-0119 Damián HernándezSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
Greg RoebuckSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
Ajeet B SinghSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0002-0853-7959 Bruno AgustiniSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0001-8735-2401 Robson ZazulaSchool of Medicine, Federal University for Latin America Integration, Foz do Iguacu, Parana, Brazil.ORCID 0000-0001-8473-050X Ana C AndreazzaDepartment of Pharmacology & Toxicology and Psychiatry, Mitochondrial Innovation Initiative (MITO2i), University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-4323-7273 Dana El Soufi El SabbaghDepartment of Pharmacology & Toxicology and Psychiatry, Mitochondrial Innovation Initiative (MITO2i), University of Toronto, Toronto, Ontario, Canada.
Hyunjin JeongDepartment of Pharmacology & Toxicology and Psychiatry, Mitochondrial Innovation Initiative (MITO2i), University of Toronto, Toronto, Ontario, Canada.ORCID 0009-0002-3594-6122 Olivia M DeanSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0002-2776-3935 Jee Hyun KimSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0002-1299-4300 Michael BerkSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.ORCID 0000-0002-5554-6946 Ken WalderSchool of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
Funding
Australian Research CouncilNational Health and Medical Research Council
6 · The paper itselfAbstract
backgroundInduced pluripotent stem cell (iPSC)-derived brain cells are widely utilised as in vitro models for several neuropsychiatric disorders, as they retain the donor's genetic profile, offering a unique opportunity to study living human brain cells and perform controlled experimental manipulations. In this study, we conducted whole transcriptome sequencing of cortical networks (co-cultures of neurons and astrocytes) derived from 12 participants with bipolar disorder (BD) and 12 participants without a history of mental health disorders. Aiming to identify new molecular mechanisms underlying the pathophysiology of bipolar disorder.
methodsiPSCs were generated by reprogramming peripheral blood mononuclear cells (PBMCs) using episomal vectors. iPSCs were then differentiated into neural progenitor cells (NPCs) and matured into cortical networks (CNs) that express markers of neurons and astrocytes. Whole transcriptome data were obtained using the Illumina NovaSeq X sequencing platform. Differential expression analysis was performed using DESeq2 in R.
resultsGene set enrichment analysis identified 191 enriched pathways in BD, 171 were downregulated, and around 10% were associated with the immune system. Of these, the toll-like signalling pathway, which is downregulated in BD, was further investigated.
conclusionOur results suggest a profound immune dysregulation in BD, with downregulation of the sensing innate immune system, particularly highlighting the immune system's role as a complex signalling network.
Indexed as
Bipolar DisorderCerebral CortexInduced Pluripotent Stem CellsSignal TransductionToll-Like ReceptorsAdultAstrocytesCoculture TechniquesFemaleHumansMaleMiddle AgedNeural Stem CellsNeuronsTranscriptomeToll-Like Receptorsbipolar disorderdepressioniPSC‐derived brain cellsmanianeurosciencepsychiatryTLR4toll‐like signalling pathway
Identifiers
PMID42549929
PMCPMC13435821
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390